Carlos M Ferrario

Author PubWeight™ 129.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002 5.02
2 Value of noninvasive hemodynamics to achieve blood pressure control in hypertensive subjects. Hypertension 2006 2.31
3 Predominance of AT(1) blockade over mas-mediated angiotensin-(1-7) mechanisms in the regulation of blood pressure and renin-angiotensin system in mRen2.Lewis rats. Am J Hypertens 2013 2.11
4 Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004 1.96
5 Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol 2005 1.92
6 Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol 2005 1.85
7 ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. Am J Physiol Regul Integr Comp Physiol 2007 1.85
8 Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 2005 1.81
9 Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: evidence for ACE2-dependent processing of angiotensin II. Am J Physiol Renal Physiol 2006 1.61
10 Diabetes, hypertension, and dyslipidemia in Mexican Americans and non-Hispanic whites. Am J Prev Med 2006 1.56
11 Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: prevention of angiotensin II-dependent hypertension. Hypertension 2009 1.52
12 Differential expression of nuclear AT1 receptors and angiotensin II within the kidney of the male congenic mRen2. Lewis rat. Am J Physiol Renal Physiol 2006 1.48
13 Impaired heart rate baroreflex in older rats: role of endogenous angiotensin-(1-7) at the nucleus tractus solitarii. Hypertension 2005 1.45
14 Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. Am J Physiol Heart Circ Physiol 2008 1.41
15 Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2005 1.40
16 Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 2007 1.36
17 Angiotensin-(1-12) is an alternate substrate for angiotensin peptide production in the heart. Am J Physiol Heart Circ Physiol 2008 1.34
18 Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab 2004 1.33
19 NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension 2007 1.32
20 Estrogen or the AT1 antagonist olmesartan reverses the development of profound hypertension in the congenic mRen2. Lewis rat. Hypertension 2003 1.32
21 Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 2002 1.30
22 Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Res 2007 1.28
23 Injections of angiotensin-converting enzyme 2 inhibitor MLN4760 into nucleus tractus solitarii reduce baroreceptor reflex sensitivity for heart rate control in rats. Exp Physiol 2008 1.24
24 Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008 1.21
25 Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats. Am J Physiol Heart Circ Physiol 2008 1.20
26 MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. Am J Physiol Cell Physiol 2008 1.20
27 Regulation of ACE2 in cardiac myocytes and fibroblasts. Am J Physiol Heart Circ Physiol 2008 1.20
28 Angiotensin-(1-7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats. J Cardiovasc Pharmacol 2008 1.20
29 Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue. PLoS One 2011 1.17
30 Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab 2008 1.15
31 Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br J Haematol 2004 1.15
32 Modulation of reflex function by endogenous angiotensins in older transgenic rats with low glial angiotensinogen. Hypertension 2008 1.12
33 Activation of local chorionic villi angiotensin II levels but not angiotensin (1-7) in preeclampsia. Hypertension 2008 1.10
34 Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 2003 1.09
35 Angiotensin-(1-7): pharmacology and new perspectives in cardiovascular treatments. Cardiovasc Drug Rev 2007 1.08
36 Cardiac kallikrein-kinin system is upregulated in chronic volume overload and mediates an inflammatory induced collagen loss. PLoS One 2012 1.08
37 Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 2008 1.06
38 Growth, metabolism, and blood pressure disturbances during aging in transgenic rats with altered brain renin-angiotensin systems. Physiol Genomics 2005 1.06
39 Novel aspects of the renal renin-angiotensin system: angiotensin-(1-7), ACE2 and blood pressure regulation. Contrib Nephrol 2004 1.06
40 Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic Ren-2 rats. Am J Physiol Heart Circ Physiol 2006 1.05
41 Baroreceptor reflex regulation in anesthetized transgenic rats with low glia-derived angiotensinogen. Am J Physiol Heart Circ Physiol 2006 1.05
42 Mineralocorticoid receptor antagonism attenuates glomerular filtration barrier remodeling in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009 1.04
43 Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. Am J Physiol Heart Circ Physiol 2007 1.04
44 Allelic variants of the human scavenger receptor class B type 1 and paraoxonase 1 on coronary heart disease: genotype-phenotype correlations. Arterioscler Thromb Vasc Biol 2005 1.04
45 Angiotensin-(1-12) requires angiotensin converting enzyme and AT1 receptors for cardiovascular actions within the solitary tract nucleus. Am J Physiol Heart Circ Physiol 2010 1.03
46 Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin. Am J Nephrol 2011 1.03
47 Nebivolol reduces proteinuria and renal NADPH oxidase-generated reactive oxygen species in the transgenic Ren2 rat. Am J Nephrol 2009 1.02
48 Enhanced renal immunocytochemical expression of ANG-(1-7) and ACE2 during pregnancy. Hypertension 2003 1.01
49 Chronic immunoneutralization of brain angiotensin-(1-12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am J Physiol Regul Integr Comp Physiol 2009 1.01
50 New angiotensins. J Mol Med (Berl) 2008 1.00
51 Aging and the brain renin-angiotensin system: insights from studies in transgenic rats. Cleve Clin J Med 2007 1.00
52 Uptake and metabolism of the novel peptide angiotensin-(1-12) by neonatal cardiac myocytes. PLoS One 2011 1.00
53 Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart. Exp Physiol 2008 1.00
54 Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension 2008 0.99
55 Rats with low brain angiotensinogen do not exhibit insulin resistance during early aging. Endocrine 2006 0.97
56 Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States, part II: treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 2005 0.96
57 Inhibition of angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. Am J Hypertens 2010 0.95
58 Sex differences in baroreflex sensitivity, heart rate variability, and end organ damage in the TGR(mRen2)27 rat. Am J Physiol Heart Circ Physiol 2011 0.95
59 Characterization of the cardiac renin angiotensin system in oophorectomized and estrogen-replete mRen2.Lewis rats. PLoS One 2013 0.95
60 Addressing the global cardiovascular risk of hypertension, dyslipidemia, and insulin resistance in the southeastern United States. Am J Med Sci 2005 0.94
61 Angiotensin receptors contribute to blood pressure homeostasis in salt-depleted SHR. Am J Physiol Regul Integr Comp Physiol 2003 0.94
62 Beneficial versus harmful effects of Angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. J Renin Angiotensin Aldosterone Syst 2007 0.93
63 Angiotensin I, angiotensin II and their biologically active peptides. J Hypertens 2002 0.93
64 Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy. Vasc Health Risk Manag 2007 0.93
65 Mechanisms linking angiotensin II and atherogenesis. Curr Opin Lipidol 2002 0.92
66 ACE2: angiotensin II/angiotensin-(1-7) balance in cardiac and renal injury. Curr Hypertens Rep 2014 0.92
67 Does angiotensin-(1-7) contribute to cardiac adaptation and preservation of endothelial function in heart failure? Circulation 2002 0.91
68 Chymase mediates angiotensin-(1-12) metabolism in normal human hearts. J Am Soc Hypertens 2013 0.90
69 Comparative effect of direct renin inhibition and AT1R blockade on glomerular filtration barrier injury in the transgenic Ren2 rat. Am J Physiol Renal Physiol 2009 0.89
70 Salt-induced renal injury in spontaneously hypertensive rats: effects of nebivolol. Am J Nephrol 2010 0.89
71 Rosuvastatin ameliorates the development of pulmonary arterial hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol 2009 0.88
72 Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol 2012 0.87
73 Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat. Regul Pept 2012 0.87
74 Pregnancy enhances the angiotensin (Ang)-(1-7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of Ang-(1-7). Endocrinology 2003 0.87
75 The protective effects of angiotensin II blockade with olmesartan medoxomil on resistance vessel remodeling (The VIOS study): rationale and baseline characteristics. Am J Cardiovasc Drugs 2006 0.87
76 Blood pressure-independent attenuation of cardiac hypertrophy by AT(1)R-AS gene therapy. Hypertension 2002 0.87
77 Concern Oxidative stress-mediated mitochondrial dysfunction contributes to angiotensin II-induced nonalcoholic fatty liver disease in transgenic Ren2 rats. Am J Pathol 2009 0.86
78 Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension. Hypertension 2012 0.86
79 Olmesartan for the treatment of arterial hypertension. Future Cardiol 2008 0.85
80 Nebivolol reduces cardiac angiotensin II, associated oxidative stress and fibrosis but not arterial pressure in salt-loaded spontaneously hypertensive rats. J Hypertens 2012 0.85
81 Restoration of the blood pressure circadian rhythm by direct renin inhibition and blockade of angiotensin II receptors in mRen2.Lewis hypertensive rats. Ther Adv Cardiovasc Dis 2012 0.85
82 Divergent regulation of circulating and intrarenal renin-angiotensin systems in response to long-term blockade. Am J Nephrol 2005 0.84
83 Characterization of angiotensin-(1-7) receptor subtype in mesenteric arteries. Peptides 2003 0.84
84 Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy. Am J Hypertens 2005 0.84
85 Angiotensin peptides modulate bradykinin levels in the interstitium of the dog heart in vivo. J Pharmacol Exp Ther 2002 0.84
86 Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors. J Am Soc Hypertens 2010 0.83
87 Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertens Res 2008 0.83
88 Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. Ther Adv Cardiovasc Dis 2009 0.83
89 Angiotensin-(1-12): a chymase-mediated cellular angiotensin II substrate. Curr Hypertens Rep 2014 0.83
90 Nebivolol improves insulin sensitivity in the TGR(Ren2)27 rat. Metabolism 2011 0.83
91 Central depletion of angiotensinogen is associated with elevated AT1 receptors in the SFO and PVN. Neurotox Res 2004 0.83
92 Reduced circulating levels of angiotensin-(1--7) in systemic sclerosis: a new pathway in the dysregulation of endothelial-dependent vascular tone control. Ann Rheum Dis 2007 0.83
93 Noninvasive hemodynamic profiles in hypertensive subjects. Am J Hypertens 2005 0.82
94 Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling. Metabolism 2013 0.82
95 Self-reported influences of hopelessness, health literacy, lifestyle action, and patient inertia on blood pressure control in a hypertensive emergency department population. Am J Med Sci 2009 0.82
96 Estrogen, nitric oxide, and hypertension differentially modulate agonist-induced contractile responses in female transgenic (mRen2)27 hypertensive rats. Am J Physiol Heart Circ Physiol 2008 0.82
97 Alterations in sympathetic ganglionic transmission in response to angiotensin II in (mRen2)27 transgenic rats. Hypertension 2004 0.81
98 Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol 2007 0.81
99 Primacy of angiotensin converting enzyme in angiotensin-(1-12) metabolism. Am J Physiol Heart Circ Physiol 2013 0.81
100 Vascular responses to Angiotensin-(1-7) during the estrous cycle. Endocrine 2004 0.81
101 Mineralocorticoid receptor-dependent proximal tubule injury is mediated by a redox-sensitive mTOR/S6K1 pathway. Am J Nephrol 2011 0.81
102 Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells. J Renin Angiotensin Aldosterone Syst 2004 0.81
103 The effect of methylenetetrahydrofolate reductase C677T common variant on hypertensive risk is not solely explained by increased plasma homocysteine values. Clin Exp Hypertens 2003 0.81
104 Angiotensin II AT1 receptor blockade normalizes CD11b+ monocyte production in bone marrow of hypercholesterolemic monkeys. Atherosclerosis 2007 0.80
105 Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. Future Cardiol 2006 0.79
106 Salt loading exacerbates diastolic dysfunction and cardiac remodeling in young female Ren2 rats. Metabolism 2013 0.79
107 Exercise training prevents development of cardiac contractile dysfunction in hypertensive TG (mREN-2)27 rats. J Am Soc Hypertens 2010 0.79
108 Mast Cell Inhibition Attenuates Cardiac Remodeling and Diastolic Dysfunction in Middle-aged, Ovariectomized Fischer 344 × Brown Norway Rats. J Cardiovasc Pharmacol 2016 0.79
109 Noninvasive ultrasound evaluation of the vertebral artery in hypertension. J Neuroimaging 2002 0.79
110 Low glial angiotensinogen improves body habitus, diastolic function, and exercise tolerance in aging male rats. Cardiovasc Endocrinol 2012 0.78
111 Hypertension-linked decrease in the expression of brain gamma-adducin. Circ Res 2002 0.78
112 The impact of changing ICD code on hypertension-related mortality in the southeastern United States from 1994-2005. J Clin Hypertens (Greenwich) 2010 0.78
113 Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 2005 0.77
114 Commentary on Tikellis et al: There is more to discover about angiotensin-converting enzyme. Hypertension 2003 0.77
115 Impact of performance improvement continuing medical education on cardiometabolic risk factor control: the COSEHC initiative. J Contin Educ Health Prof 2014 0.77
116 Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7). Ther Adv Cardiovasc Dis 2011 0.76
117 Differential effect of low dose thiazides on the Renin Angiotensin system in genetically hypertensive and normotensive rats. J Am Soc Hypertens 2010 0.76
118 Of gender, statins, and coronary artery interventions. Ther Adv Cardiovasc Dis 2008 0.76
119 Increased hypothalamic angiotensin-(1-7) levels in rats with aortic coarctation-induced hypertension. Peptides 2007 0.76
120 Emergency department patients self-report higher patient inertia, hopelessness, and harmful lifestyle choices than community counterparts. J Clin Hypertens (Greenwich) 2012 0.76
121 The never-ending story of angiotensin peptides: beyond angiotensin I and II. Circ Res 2013 0.76
122 Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction. J Cardiometab Syndr 2006 0.75
123 Response to "Angiotensin-(1-7) in the central regulation of blood pressure and renin-angiotensin system". Am J Hypertens 2013 0.75
124 Therapeutic Advances in Cardiovascular Disease. Editorial. Ther Adv Cardiovasc Dis 2015 0.75
125 Association between antihypertensive agent use and hospital admissions in a managed care population. Am J Med Sci 2004 0.75
126 On the selective inhibitors of Cyclooxygenase-2: do we have a last word? Ther Adv Cardiovasc Dis 2008 0.75
127 Editorial: journal accomplishments in just one short year. Ther Adv Cardiovasc Dis 2009 0.75
128 Self-reported cardiovascular disease risk factors and associated hopelessness in African American participants of a church-placed health screening program. Ethn Dis 2014 0.75
129 New approaches to hypertension management: always reasonable but now necessary. Am J Hypertens 2005 0.75
130 Memorial. Ther Adv Cardiovasc Dis 2009 0.75
131 Questions to ponder. Ther Adv Cardiovasc Dis 2008 0.75
132 Left ventricular geometric patterns after 1 year of antihypertensive treatment. J Clin Hypertens (Greenwich) 2005 0.75
133 Comparative effects of a novel angiotensin-converting enzyme inhibitor versus captopril on plasma angiotensins after myocardial infarction. Pharmacology 2014 0.75